News EU probes Aspen price gouging allegations Aspen pulled drugs from some countries that rejected price hikes, says EU.
News The week that turned the cancer immunotherapy market on its ... Contrasting fortunes for Roche and AZ in a week of drama.
News Drama as Roche's Tecentriq fails in key bladder cancer trial Roche has been shocked by the late-stage trial failure of its immunotherapy Tecentriq in bladder cancer, a setback which could cost it billions if the drug loses its licence.
News CEO Meek looks to boost Ipsen with drug acquisitions Could French biotech snap up remaining rights to pancreatic cancer drug?
News EUSA Pharma approval fills gap in neuroblastoma market Company can move in after United Therapeutics withdrew its product Unituxin
Views & Analysis Deep Dive: Oncology magazine launched today Are cancer screening and diagnosis swift enough, and how effective are the latest tailored drugs?
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
